Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

Abstract excerpt

Abstract BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAFV600-mutant melanoma, but acquired drug resistance is almost universal. We sought to identify the core resistance pathways and the extent of tumor heterogeneity during disease progression. We show that mitogen-activated protein kinase reactivation mechanisms were detected among 70% of disease-progressive tissues, with...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to HER2/EGFR in Cancer Research
• Share to Melanoma and MAPK Pathways